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Pharmacopoeial impuritiesAbstract This study reports for the ﬁrst time about a stability indicating RP-HPLC method for
quantitative determination of Praziquantel (PZQ) in bulk powder and dosage form and in presence
of its pharmacopoeial impurities. The chromatographic separation was carried out on (Caltrex
AI) calixarene column, a relatively new packing material. Chromatography was done using an iso-
cratic binary mobile phase consisting of ACN and 25 mM ammonium acetate (NH4Ac) in the ratio
of 40:60 at ﬂow rate of 1 mL min1, 30 C and 210 nm wavelength for detection. The elution time of
PZQ was found to be 6.15 ± 0.03 min. The method was validated for system suitability, linearity,
precision, limits of detection and quantitation, speciﬁcity, stability and robustness. The robustness
study was done for small changes in temperature, ﬂow rate, wavelength of detection and % of ACN
in mobile phase. Stability tests were done through exposure of the analyte solution to ﬁve different
stress conditions: Reﬂux with 1 N HCl, reﬂux with 1 N NaOH, reﬂux with 30% H2O2, thermal deg-
radation of powder and exposure to UV radiation. Limits of detection and quantiﬁcation were
found to be 0.56 and 1.70 lg mL1, respectively. The recovery value of this method was
100.30%± 1.10 and the reproducibility was within 1.31.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
PZQ is the drug of choice for the treatment of schistosomiasis
and most of the trematode infections. It is an anthelmintic with
a broad spectrum of activity against trematodes and against
cestodes. PZQ has a good safety and therapeutic proﬁle. It
has been widely used in community-based schistosomiasis con-
trol programs. For example, in Egypt and China, more than
100 million doses have been administered over the past two
decades (Chen, 2005; Fenwick et al., 2006).
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determination of praziquantel, including spectroﬂuorimetry
(Putter, 1979; Putter and Held, 1979), gas chromatography
(Saleh and Schnekenburger, 1992) and high-performance liquid
chromatography (Xiao et al., 1983; Anurak and Kesara, 2004;
Moutasim et al., 2004; Rubiana et al., 2006; Jia et al., 2007;
Jiangeng et al., 2010; Kulik et al., 2011; British pharmacopoeia,
2011; Lucie Havlı´kova´ et al., 2012).
All drugs, according to current goodmanufacturing practice,
must be tested with a stability-indicating assay before release.
The intrinsic stability of the molecule and validation of the sta-
bility-indicating power of the analytical procedures used can be
identiﬁed through stress testing. It was felt that aHPLCmethod
of analysis that separates the drugs from the degradation prod-
ucts formedunder ICH-suggested conditions (hydrolysis, oxida-
tion, photolysis, and thermal stress) would be of general interest.
These studies provide valuable information about the inherent
stability of a drug and help in the validation of analytical meth-
ods to be used in stability studies (ICH, 2003). Chromatographic
methods have taken priority over conventional analysis meth-
ods because of the requirement for separation of several compo-
nents during stability analysis. In addition to separation of
multiple components, chromatographic methods have other
advantages, which are: they are more accurate and sensitive,
even for small quantities of degradation products. In a previous
study triethylamine was used for the separation of PZQ from
other anthelmintics (Lucie Havlı´kova´ et al., 2012). Ion-pairing
agents as triethylamine are known to deteriorate the stationary
phases (Snyder and Kirkland, 1979; Snyder et al., 1997).
As far as we know, there is no previous stability indicating
quantitation method in the literature for determination of
PZQ. The alone study which reported about photo-thermal
stability (Moutasim et al., 2004) aimed to ﬁnd the best excipi-
ent to increase the stability of PZQ in the dosage form. The
objective of this study was, therefore, to develop a new, simple,
rapid, precise, accurate, and speciﬁc stability-indicating HPLC
method for quantitative determination of PZQ in tablet for-
mulation and in presence of its impurities without using ion-
pairing agents.
2. Materials and methods
2.1. Chemicals and reagents
All chemicals and reagents are at least of analytical grade.
Bidistilled Water was used. Ammonium acetate (NH4Ac) was
purchased from (Merck, Germany). ACN was of HPLC-grade
(J.T. Baker, Holland).
100% purity pharmaceutical grade PZQ obtained from
(EIPICo, Egypt) was used (EIPICo, Egypt). Pharmaceutical
formulation, Distocid tablets (containing 600 mg PZQ per
tablet) were obtained from Egyptian market.
2.2. Instrumentation
Agilent HPLC series 1200 (Agilent technologies, Germany)
consists of solvent pump (model G1311A), autosampler (model
G1329A), column compartment (model G1316A) and UV
detector (model G1314A).
SUNTEST CPS+ was used for UV-radiation for photo-
degradation of PZQ.2.3. Column
Calixarene stationary phase column (Caltrex AI, Kromasil Si
100/5 lm, 4.0 · 125 mm) was obtained from (Syntrex Roth
and Menyes GbR., Germany).
2.4. Chromatography
The experiments were performed with isocratic elution. The
binary mobile phase consisted of ACN in 0.02 M NH4Ac,
40:60 V/V. The eluents were degassed before running, set at
a ﬂow rate of 1 mL min1 and column temperature at 30 C.
A volume of 10 lL of samples was injected per run and eluates
were detected using a UV-detector at k= 210 nm.
2.5. Solutions preparation
2.5.1. Preparation of stock and standard working solutions
The stock solution of PZQ (1 mg mL1) was prepared by dis-
solving 100 mg of PZQ in (1:1) ACN:water to make 100 mL
of solution. The standard working solutions were prepared by
diluting aliquots of the stock solution to obtain concentrations
ranging from 0.1 to 100 lg mL1. The calibration graph was
constructed by plotting the peak areas obtained at a wavelength
of 210 nm versus the corresponding injected concentrations.
2.6. Sample preparation
The contents of 10 tablets of Distocid 600 mg were accurately
weighed and ground to a ﬁne powder. To an accurately weighed
portion of the powder equivalent to one tablet, 250 mL (1:1)
ACN:H2O was added then the solution was left in the ultra-
sonic bath for 10 min. After that the solution was ﬁltered and
the ﬁrst 10 mL was rejected then 2 mL of ﬁltrate was diluted
to 100 mL using same solvent.
2.7. Stability tests
Forced degradation studies were performed to ensure the sta-
bility-indicating properties and speciﬁcity of the method. Inten-
tional degradation was attempted using acid, base, hydrogen
peroxide, thermal and UV-radiation. A degradation sample
was prepared by dissolving 25 mg of PZQ in 25 mL (ACN:-
H2O, 1:1) through shaking and sonication. Then 10 mL of this
solution was taken in each of three 50 mL round bottomed
ﬂasks to perform the ﬁrst three degradation tests. To the ﬁrst
ﬂask, 10 mL of 1 N HCl was added for acidic degradation.
To the second ﬂask, 10 mL of 1 N NaOH was added for basic
degradation. To the third ﬂask, 10 mL of 30%H2O2 was added
for oxidative degradation. All the three ﬂasks were reﬂuxed for
about 4 h. After completing degradation treatments, samples
were allowed to cool to room temperature and treated as fol-
lows: The pH values of the ﬁrst and second ﬂasks were neutral-
ized with 1 N NaOH and 1 N HCl, respectively. To the third
ﬂask 1 N sodium bisulﬁte solution was added to destroy
H2O2. The volume of all the three ﬂasks was adjusted to
50 mL with (ACN:H2O, 1:1).
For thermal degradation, PZQ powder was dispersed onto
a Petri-dish and left in oven at 60 C for 4 h then the solution
was prepared from it in a concentration of 0.2 mg/mL using
(ACN:H2O, 1:1) as solvent. For degradation through UV-radi-
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4 h then the radiated solution was diluted with (ACN:H2O,
1:1) to 10 mL, then ﬁnally injected into chromatograph and
compared with control sample.
The speciﬁed pharmacopoeial PZQ impurities A and B (US
pharmacopoeia, 2011) prepared in a concentration of 0.1 mg/mL
(ACN:H2O, 1:1) as solvent were also separated in the presence
of PZQ.
3. Results and discussion
When separation was done using binary mobile phase consist-
ing of ACN and H2O, there was no complete separation be-
tween the intact drug and the degradants or impurities; so
inorganic salts were added to water. The best baseline separa-
tions were obtained when NH4Ac was used. When the content
of ACN in mobile phase was greater than 40%, the retention
time shortened but the peak of the intact drug was co-eluted
with the peaks of degradants. On contrast, when the content
of ACN in the mobile phase was less than 40%, the retention
time became longer without any improvement in separation; so
40% ACN was used as organic modiﬁer. 210 nm was used as
the wavelength of detection because it has the advantage over
the greater wavelength in that at it all peaks of degradants and
intact drug can be detected.
3.1. System suitability
The results of three runs indicate high system suitability (Table
1). The tR-value of PZQ is 6.15 ± 0.03 min. The RSD of peak
area is 0.51%.Table 1 System suitability and linearity and regression data.
Parameters
System suitability
tR ± SD (min) 6.15 ± 0.03
N 2000
k 5.5
Linearity range (lg mL1) 5–100
Detection limit (lg mL1) 0.56
Quantitation limit (lg mL1) 1.70
Regression data
Slope (b) 44.6
Intercept (a) 11.797
Coeﬃcient of determination (R2) 0.9996
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Figure 1a Praziquante3.2. Linearity and range
Seven concentrations of PZQ solution ranging from 0.1 to
100 lg mL1 were analyzed. The graph of the peak area against
concentration proved linearity in the range of 5–100 lg mL1
and the linearity equation is: Y= 44.601X  11.797. Regression
coefﬁcient was found to be 0.9996. The limit of detection (LOD)
deﬁned as the injected quantity giving S/N of 3 (in terms of peak
height), was found to be 0.56 lg mL1. The limit of quantiﬁca-
tion (LOQ), deﬁned as the injected quantity giving S/N of 10
(in terms of peak height),was found to be 1.70 lg mL1 (Table 1).
3.3. Accuracy and speciﬁcity of the method
The accuracy of the method was determined by recovery
experiments applying standard addition technique (n= 5)
and showed high accuracy with recovery of 100.30 ± 1.10%.
The comparison between the chromatogram of the raw
PZQ (Fig. 1a) and that of extracted PZQ from tablets
(Fig. 1b) indicates that the excipients in the formulation did
not interfere with the determination of PZQ. Also USP impu-
rities A and B, which come through chemical synthesis of the
drug, did not interfere (Fig. 1c).
When diloxanide furoate, paracetamol, trimethoprim and
albendazole were injected simultaneously with PZQ, only
albendazole interfered.
3.4. Stability of the analytical solution and stability tests
Stability of the standard solution was studied by injection of
the prepared solution at periodic intervals into the chromato-
graph up to about ﬁve days. The results indicate that the RSD
of the peak area was within 1.50%.
The results of stress degradation indicate that PZQ is
strongly affected with reﬂux with NaOH (Fig. 2a) and H2O2
(Fig. 2b). Moutasim et al. (2004) found that the increase of
pH led to increase of degradation of PZQ. This ensures the
stronger effect of NaOH than that of HCl in this study. The
strong effect of oxidative degradation can be due to the pres-
ence of amino-groups in PZQ structure. Reﬂux with HCl
(Fig. 2c) led to degradation of PZQ but the effect here is weak-
er than in cases of H2O2 and NaOH. Thermal (Fig. 2d) and
UV-light exposure (Fig. 2d) gave the minimum effect on
PZQ. Although there were several degradants, there was not
any interference with the peak of the intact drug indicating
that the method is stability indicating. (see Fig. 2e).min5 30 35 40 45
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Figure 1b Praziquantel from Distocid tablets.
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Figure 1c PZQ USP related impurity A (4.3 min) and PZQ USP related impurity B (12.8 min).
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Figure 2a Praziquantel after treatment with 1 N NaOH.
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Figure 2b Praziquantel after treatment with 1 N HCl.
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Figure 2c Praziquantel after treatment with H2O2.
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Figure 2d Praziquantel after exposure to UV light at suntest for 4 h.
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Figure 2e Praziquantel powder after exposure to heat at 60 C for 4 h.
Table 2 Reproducibility and precision (n= 5).
Injected amount (lg mL1) Intra-day (n= 5) Inter-day (n= 5)
Observed amount (lg mL1) CVa Accuracy (%)b Observed amount (lg mL1) CVa Accuracy (%)b
20.0 20.07 0.51 100.3 19.42 1.86 97.08
40.0 40.24 0.38 100.6 38.94 1.22 97.35
50.0 49.83 0.23 99.7 48.16 0.98 96.32
a Coefﬁcient of variation (CV) = S.D. · 100/mean.
b Accuracy (%) = observed concentration · 100/used concentration.
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Table 3 Statistical analysis of results obtained by the proposed method applied on Distocid tablets
compared with a reported method.
Parameters Distocid tablets Reference method
(Rubiana et al., 2006)
n 5 8
Mean recovery 98.70 99.33
Variance 3.90 2.41
±S.D. 1.97 1.55
±R.S.D. 2.00 1.56
Student’s-t test 0.64 (2.20)a
F-test 1.62(4.12)b
a and b are the theoretical Student’s-t test values and F-ratios at p_0.05.
Table 4 Robustness of the proposed method.
Slight changes in Temp. (C) Flow rate (mLmin1) ACN (%) Detection wavelength (nm) Buﬀer conc. (mM)
28, 30 and 32 0.9, 1.0 and 1.1 38, 40 and 42 208, 210 and 212 20, 25 and 30
Aﬀected factor Peak area K0 Peak area tR Peak area K0
C.V. (%) 0 0.94 1.0 0.42 2.0 0.18
S40 H. Hashem et al.3.5. Reproducibility and precision of the method
Results (Table 2) show that there were high intra- and inter-
day precisions (both within 2.0%). Intra-day precision was
assessed through the injection of three different concentrations
of the standard solution ﬁve times during a day. The same
procedure was done for inter-day precision test except that
the injection of the samples was every day for ﬁve days.
3.6. Application
The analysis of PZQ in the formulation Distocid tablets by
the proposed method (Table 3) showed a mean recovery of
98.70 ± 2.0% which was statistically comparable to reported
method (Rubiana et al., 2006).
3.7. Robustness of the method
The robustness of the present method was evaluated in terms
of small changes in temperature, ﬂow rate, content of ACN
in mobile phase, wavelength of detection, salt concentration
and injection volume (Table 4). The results show that the slight
variations in the examined factors had no signiﬁcant effect on
the shape of the peak.4. Conclusions
A valid and fast stability indicating HPLC-method for quanti-
ﬁcation of PZQ is established. Compared with the reported
methods, this method represents the ﬁrst report about a stabil-
ity indicating method for the determination of PZQ in short
time. With the proposed method a satisfactory separation of
PZQ from the degradation products and impurities, extended
linear range and rapid analysis time were carried out. A high
recovery of PZQ in formulation was achieved. The proposed
method ensured a precise and accurate determination of
PZQ in oral tablet formulation. No interference from the
excipients was noticed.Acknowledgment
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